The Readout

The Readout Meghana Keshavan

STAT Plus: The biotech news roundup to start your week

The Readout Meghana Keshavan

STAT Plus: A setback for the tau approach to Alzheimer’s

The Readout Meghana Keshavan

STAT Plus: The semaglutide drought may be ending

The Readout Elaine Chen

STAT Plus: Lilly’s rare stumble, and GSK’s big vaccine miss

The Readout Elaine Chen

STAT Plus: GSK acquires autoimmune drug candidate

The Readout Meghana Keshavan

STAT Plus: The biotech news you need to read today

The Readout Elaine Chen

STAT Plus: Wojcicki projects confidence amid 23andMe stumbles

The Readout Elaine Chen

STAT Plus: ‘Switchable’ CAR-T startup raises $112 million

The Readout STAT Staff

STAT Plus: The biotech updates you need to read this morning

The Readout Meghana Keshavan

STAT Plus: Potential competition for RSV prophylactic Beyfortus

The Readout Elaine Chen

STAT Plus: More evidence on GLP-1s and opioid addiction

The Readout Elaine Chen

STAT Plus: A controversial approval for Novocure’s device

The Readout Meghana Keshavan

STAT Plus: The biotech news you missed this weekend

The Readout Meghana Keshavan

STAT Plus: A setback for the Denali-Sanofi partnership

The Readout Meghana Keshavan

STAT Plus: A crack of light for Pfizer

The Readout Elaine Chen

STAT Plus: Prime Medicine lays off workers as it trims pipeline

The Readout Elaine Chen

STAT Plus: Scholar Rock sees SMA data boosting obesity effort

The Readout Meghana Keshavan

STAT Plus: The biotech news stories you need to read this morning

The Readout STAT Staff

STAT Plus: WuXi looks to sell assets as BIOSECURE Act looms

The Readout Elaine Chen

STAT Plus: Dockworker strike puts drug supplies at risk

The Readout Elaine Chen

STAT Plus: Lilly invests $4.5 billion in a new research hub

The Readout Elaine Chen

STAT Plus: The latest obesity drug updates happening right now

The Readout Meghana Keshavan

STAT Plus: A radiopharmaceuticals startup raises $175 million

The Readout Meghana Keshavan

STAT Plus: Why are Genentech cancer researchers worried?

The Readout Elaine Chen

STAT Plus: Biotech’s real estate market is still upside down

The Readout Elaine Chen

STAT Plus: The science behind Summit’s success, 23andMe’s fate, and more biotech news updates

The Readout Elaine Chen

STAT Plus: Metsera’s GLP-1 drug has potential for monthly dosing, new data show

The Readout Meghana Keshavan

STAT Plus: The biotech news you need to start the week

The Readout Meghana Keshavan

STAT Plus: Are generalist investors good or bad for biotech?